The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•6 May 2026•

1 min read

Citigroup Raises Establishment Labs Price Target Following Robust Q1 Revenue Growth

Key Facts

1Citigroup maintained a Neutral rating on Establishment Labs while raising the price target from $65 to $76.

2The company reported Q1 revenue of $59.9 million, representing a 44.7% year-over-year increase.

3The company achieved a positive adjusted EBITDA of $1.2 million and narrowed its quarterly loss to $0.40 per share.

Citigroup has increased its price target for Establishment Labs (ESTA) to $76 from $65, while maintaining a Neutral rating on the stock. The revision follows a strong first-quarter performance where the company reported revenue of $59.9 million, a significant 44.7% increase year-over-year. Notably, the firm achieved a positive adjusted EBITDA of $1.2 million and successfully narrowed its quarterly loss to $0.40 per share. This growth was largely driven by robust sales of Motiva breast implants in the U.S. market. Consequently, the company has raised its full-year guidance, signaling confidence in its operational momentum and expanding footprint within the medical technology sector.